Showing results (1-10 of 164) with videos related to
Sort By:
Pageof 17
Clinical Pharmacology and Therapeutics|March 1, 1992
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphismS H Sindrup, K Brøsen, L F GramTherapeutic Drug Monitoring|September 1, 1990
Nonlinear kinetics of imipramine in low and medium plasma level rangesS H Sindrup, K Brøsen, L F GramClinical Pharmacology and Therapeutics|December 29, 1999
The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levelsS H Sindrup, C Madsen, K Brøsen, et al.Clinical Pharmacology and Therapeutics|December 1, 1996
The hypoalgesic effect of tramadol in relation to CYP2D6L Poulsen, L Arendt-Nielsen, K Brøsen, et al.European Journal of Clinical Pharmacology|October 17, 1998
Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronideL Poulsen, L Riishede, K Brøsen, et al.Clinical Pharmacology and Therapeutics|May 21, 2005
Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadolS Laugesen, T P Enggaard, R S Pedersen, et al.European Journal of Clinical Pharmacology|January 1, 1993
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteineK Brøsen, J G Hansen, K K Nielsen, et al.European Journal of Clinical Pharmacology|January 1, 1989
Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve functionS H Sindrup, B Ejlertsen, A Frøland, et al.Clinical Pharmacology and Therapeutics|November 1, 1992
The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathyS H Sindrup, U Bjerre, A Dejgaard, et al.Pageof 17